Steven Barth Discusses Regulatory Hurdles for Strategic Buyers
October 15, 2024
S&P Global
Foley & Lardner LLP partner Steven Barth commented on the regulatory hurdles strategic buyers face in the S&P Global article, “Private equity fuels TMT M&A for 2nd consecutive quarter in Q3.”
“We live in a current regulatory environment where we can no longer provide reliable advance advice to our clients about whether a deal will likely receive regulatory approval,” Barth explained, highlighting that consequentially, transactional attorneys are emphasizing caution when advising clients.
“We like to be right. And on deals that never get submitted for approval, we’re always right,” Barth added.
Barth’s commentary also appeared in the S&P Global article, “Private equity deals regain momentum; buyout shops lead TMT sector M&A.”
People
Related News
September 18, 2026
In the News
Patrick Daugherty Authors Article on Navigating Proposed SEC Crypto Asset Regulations
Foley & Lardner LLP partner Patrick Daugherty authored the Columbia Law School’s Blue Sky Blog article, “How to Advise Token Developers in Light of Proposed SEC Regulation Crypto Assets.”
September 17, 2026
In the News
Foley Featured in Law.com for Guiding Kontoor Brands in Sale of Lee®
Foley & Lardner LLP partner Bryan Schultz is featured for leading the Foley deal team which advised Kontoor Brands in the sale of its Lee® business in Law.com's “How the Deal Got Done” series.
September 15, 2026
In the News
David Rosen Shares Insights on FDA Efforts to Accelerate Human Clinical Trials
Foley & Lardner LLP partner David Rosen shared insights in the recent Law360 article, “FDA Seeks Applications For Project To Speed Up Human Trials,” on the FDA's pilot program pairing pharmaceutical companies with research institutions to accelerate human clinical trials.